argenx SE (MEX:ARGX) Accumulated Depreciation : MXN0 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is argenx SE Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

argenx SE's quarterly accumulated depreciation increased from Sep. 2024 (MXN0 Mil) to Dec. 2024 (MXN-609 Mil) but then stayed the same from Dec. 2024 (MXN-609 Mil) to Mar. 2025 (MXN0 Mil).

argenx SE's annual accumulated depreciation increased from Dec. 2022 (MXN-352 Mil) to Dec. 2023 (MXN-385 Mil) and increased from Dec. 2023 (MXN-385 Mil) to Dec. 2024 (MXN-609 Mil).

argenx SE Accumulated Depreciation Historical Data

The historical data trend for argenx SE's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Accumulated Depreciation Chart

argenx SE Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accumulated Depreciation

Get a 7-Day Free Trial

-180.44

-286.36

-351.84

-384.89

-608.95

argenx SE Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accumulated Depreciation	Get a 7-Day Free Trial															-	-	-	-608.95	-

argenx SE Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

argenx SE Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of argenx SE's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (MEX:ARGX) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

ARGX:USA ARGXb:UK 0QW0:UK 1AEA:Germany 1AE:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria

Address

Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website

https://www.argenx.com

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.